Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Smith

Optometrist York, PA Doctor of Optometry

NPI 1356408975 CMS profile 151527

2295 N Susquehanna Trl Ste B, Ste B, York, PA 17404

Open in the dashboard

General payments

$2,472

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Smith of York, PA is reported in the CMS Open Payments database as having received $2,472 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $396 19
2024 General $494 16
2023 General $469 18
2022 General $324 18
2021 General $421 19
2020 General $164 7
2019 General $207 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Smith
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Matthew Smith were reported at $396. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Matthew Smith Optometrist median Middle half National median
2019 $207 $159 $67–$371 $163
2020 $164 $72 $29–$165 $114
2021 $421 $125 $46–$292 $132
2022 $324 $162 $66–$374 $149
2023 $469 $177 $72–$406 $160
2024 $494 $188 $77–$427 $164
2025 $396 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $312 18 payments
  2. CooperVision Inc. $297 13 payments
  3. Sun Pharmaceutical Industries Inc. $280 11 payments
  4. Bausch & Lomb Americas Inc. $277 15 payments
  5. Johnson & Johnson Vision Care, Inc. $217 9 payments
  6. Alcon Vision LLC $177 11 payments
  7. Tarsus Pharmaceuticals, Inc. $173 6 payments
  8. Oyster Point Pharma, Inc. $148 6 payments
  9. AbbVie, Inc. $112 5 payments
  10. Aerie Pharmaceuticals, Inc. $100 1 payment
  11. Other $380 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,472 109 payments
Products named General payments · program years 2019–2025
  1. XIIDRA Ophthalmology $375 21 payments
  2. Cequa $280 11 payments
  3. MIEBO $207 12 payments
  4. MyDay Contact Lens $200 11 payments
  5. XDEMVY $173 6 payments
  6. Acuvue $142 6 payments
  7. rhopressa $100 1 payment
  8. rocklatan $100 1 payment
  9. XIIDRA Ophthalmology $91 6 payments
  10. TYRVAYA $88 4 payments
  11. Other $1,021 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

535

Median for Optometry: 120

Drug cost

$100,498

Median for Optometry: $8,864

Branded share of claims

25.6%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xiidra Lifitegrast Brand 27 $33,747
Lumigan Bimatoprost Brand 41 $21,821
Restasis Cyclosporine Brand 17 $14,342
Cyclosporine Generic 17 $9,559
Vyzulta Latanoprostene Bunod Brand 21 $5,707
Travoprost Generic 30 $5,290
Brimonidine Tartrate Generic 51 $4,070
Latanoprost Generic 218 $2,706
Combigan Brimonidine Tartrate/Timolol Brand 13 $2,515
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 18 $394

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$41,351

Medicare's payments for the services billed

Medicare patients

281

Average age 74

Services billed

934

157 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 29%
Chronic kidney disease 23%
Ischemic heart disease 22%
Osteoporosis 18%
Atrial fibrillation 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $48
$48 — —
MIEBO
  • Bausch & Lomb Americas Inc. $41
$41 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $41
$41 27 —
LUMIGAN
  • AbbVie, Inc. $39
$39 41 —
TYRVAYA
  • Oyster Point Pharma, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record